The aim of the study was to analyze the real cost of single or tandem high-dose chemotherapy (HDC) and peripheral blood progenitor cell autologous transplant (PBPCT) in patients with breast cancer. We analyzed the costs of 40 PBPCT performed in 20 patients. Tandem transplant was planned for each patient. Resources used and direct costs were identified for each patient. The study was carried out using the hospital perspective and monetary values were reported in 1999 Euro. The mean cost of whole procedure for single transplant was 20 816.63 Euro, while the mean cost of tandem transplant was 38 770.83 Euro. The cost distribution in the two groups was similar: the most expensive phase of procedure was the supportive phase post transplant (about 60% of total cost), with the categories of cost most represented being professional fees (about 28%) and pharmacy (about 35%). Awaiting more convincing trials of the clinical advantage of HDC in breast cancer, our analytical evaluation of transplant costs for different therapeutic options, single or tandem, permits identification of the most expensive categories in order to intervene for cost savings. Bone Marrow Transplantation (2001) 27, 1031-1035. Keywords: cost analysis; high-dose chemotherapy; peripheral blood progenitor cell autograft; breast cancer High-dose chemotherapy (HDC) and peripheral blood progenitor cell autologous transplant (PBPCT) have been extensively used in patients with breast cancer.
High-dose chemotherapy (HDC) and peripheral blood progenitor cell autologous transplant (PBPCT) have been extensively used in patients with breast cancer. 1 Although trials evaluating the clinical benefit of this approach are under investigation, 2, 3 the treatment costs restrict its use both on and off clinical trials. The knowledge of the cost distribution is important in reducing costs and in negotiating reimbursement strategies for individual institutions. [4] [5] [6] In this study we carried out a retrospective analysis of the costs of PBPCT in 20 patients with metastatic or highrisk breast cancer treated in an intensive care unit at an Italian hospital. The patients received double high-dose chemotherapy followed by PBPC support. The cost analysis was conducted using the hospital perspective. The aim of the study was to analyze the real cost of the procedure considering each intervention involved in order to identify which part of the procedure was most expensive and if there was the possibility for cost saving.
Patients and methods

Patients
Forty consecutive PBPCT were performed in 20 patients with breast cancer. Tandem transplant was planned for each patient. Seven patients had metastatic disease and 13 had high-risk breast cancer with more than 10 positive nodes.
All patients had received standard chemotherapy regimens before HDC including CEF (5-fluorouracil, cyclophosphamide and epirubicin) or docetaxel + epirubicin. Highrisk patients received HDC after four courses of standard chemotherapy. Metastatic breast cancer patients were treated with HDC only if in complete or partial response, receiving a median of two cycles after response.
PBPC collections were performed after a standard cycle of chemotherapy followed by G-CSF (5 g/kg/day) given subcutaneously from day +3 until end of leukapheresis (LK). A minimum of 2 × 10 6 /kg CD34 + cells was collected to support each HDC. To support tandem transplant 14 patients had two LK, five only one LK and one patient needed 4 LK. Venous access for apheresis was obtained using a temporary femoral vein catheter. The apheresis product was cryopreserved and in 10 patients CD34 + cell selection was made. PBPC collection was performed entirely on an outpatient basis.
Before HDC the patients underwent clinical and laboratory investigations in order to evaluate the feasibility of the HDC procedure; the central venous catheter was inserted in this phase.
Patients were conditioned with chemotherapy alone: high-dose melphalan (140 mg/m 2 ) or ICE (ifosfamide + carboplatin + etoposide). During transplant and post-transplant periods, all patients were hospitalized in an intensive care hematological unit. Daily surveillance began on the first day of hospitalization and was continued throughout the hospital stay. All patients were isolated in single or double rooms with positive air-flow. Oral decontamination Bone Marrow Transplantation with non-absorbable antibiotics and amphotericin B was planned. All patients received G-CSF (5 g/kg/day) given subcutaneously after HDC from day +3 until granulocyte recovery (granulocyte count Ͼ1 × 10 9 /l). Platelet transfusion was given when the platelet count was less than 20 × 10 9 /l or in cases of bleeding. Packed red cells were transfused to maintain the hemoglobin level above 8 g/dl. All blood components were irradiated with a dose of 25 Gy before transfusion. Broad-spectrum i.v. antibiotics were given in cases of temperature у38°C and modified according to standard practice for neutropenia. Patients were discharged when they fulfilled the following criteria: neutrophils Ͼ1 × 10 9 /l and unsupported platelets Ͼ20 × 10 9 /l. These values should be maintained for at least 2 consecutive days in the absence of fever and significant nonhematological toxicity.
The choice and schedule of administration of drugs followed institutional protocols.
Analysis of costs
Since the cost analysis was conducted from the point of view of the hospital, indirect costs (costs not directly attributable to the treatment: work time lost by patient, caregiver and productivity losses due to morbidity, etc) were not considered. Resources used and direct costs were identified for each patient. All costs on which it was felt that PBPCT would have an impact were included. The costs were subdivided into four main groups: mobilization and collection of PBPC, preparative phase before transplant, conditioning and transplant phase, supportive phase post transplant.
For the harvesting procedure the costs included the insertion of a femoral catheter, the administration of G-CSF, the cost of leukapheresis and cryopreservation, laboratory investigations and clinic visits. The cost of standard chemotherapy was not included since it was not directly related to the transplant procedure. The preparative phase included the insertion of a CVC catheter, clinic visits and diagnostic and laboratory investigations. Neither phase included hospitalization costs since they were performed on an outpatient basis.
The next two phases included the hospitalization costs and were composed of the following elements: medical staff, nursing staff, hospital overheads, room cost, equipment and supplies. In the pre-transplant period were included conditioning regimen, cost of drugs and laboratory investigations. In the post-transplant phase drugs, growth factors, blood products and laboratory investigations were considered. These costs were calculated from the day of admission to hospital until the day of discharge.
The cost of resources employed are reported according to the real mean costs to the hospital and not charges. The following categories of costs were considered: professional fees, stem cell harvest, blood products, diagnostic and laboratory, pharmacy, room cost and overhead.
The professional fees, the room and overheads were derived from the hospital's analytic accounting system.
The drugs costs were obtained from wholesale price lists applied to the Azienda Ospedaliera S Camillo-Forlanini hospital pharmacy. All costs were calculated using the unit price multiplied by the total number of units and the remaining cost of hospitalization from the hospital finance department.
The cost of leukapheresis, cryopreservation and blood products were obtained from the Blood Bank tariff.
Bacteriology, virology, biochemistry, hematology and immunology tests were evaluated according to the Supplement of Gazzetta Ufficiale della Repubblica Italiana on 14 September 1996 No. 216.
Monetary values for 1999 prices in Euro were used for all components.
Results
Twenty patients received tandem high-dose chemotherapy followed by peripheral blood progenitor cell support. Ten patients received CD34
+ selected cells and 10 received unmanipulated graft. A median of 5 × 10 6 /kg CD34 + cells were reinfused. All patients engrafted reaching neutrophils Ͼ500/l and platelets Ͼ20 000/l within 10 and 12 days, respectively. The median number of red blood cell and platelet transfusions was three and three, respectively. No toxic deaths were observed and significant unusual side-effects were limited to hemorrhagic cystitis (one episode) and veno-occlusive disease (one episode). The median length of stay was 22 days (range 18-34): 8 days for conditioning phase and 14 days for supportive phase post transplant. No significant differences in either hematopoietic recovery or hospitalization time between patients who received unmanipulated or CD34
+ selected cells was observed. No readmissions to hospital within 30 days after discharge were recorded.
The mean cost of whole procedure for single transplant was 20 816.63 Euro, while the mean cost of tandem transplant was 38 770.83 Euro. The cost of a tandem transplant was evaluated by adding to the cost of the first transplant the cost of the second leukapheresis, cryopreservation, conditioning and transplant phase and supportive phase post transplant. randomized clinical trial and it does not represent common practice in this setting, the relative cost was considered separately. The additional cost of CD34 + cell selection was 3615.20 Euro for both single or tandem transplant because a single positive selection was performed on the whole apheresis product.
Discussion
Although HDC with stem cell support has been increasingly used in patients with breast cancer, the high cost of such therapeutic approach represents a significant barrier to 4, 6 This is also the reason why many insurance companies in the USA consider this therapy too expensive for standard practice. 8 Our study analyzed breast cancer patients treated in our intensive care ward with HDC and PBPC support and was directly based on data from clinical records. Patients included in a phase II trial for CD34 + cell selection were considered separately in order to avoid the discrepancies between routine practice and economic outcomes in the clinical trial. The advantage of our study is that we have been able to evaluate the real costs of the procedure and not the charges as occurs in most American studies. [9] [10] [11] In fact, in the USA charges to third-party payers, such as government or private insurance agencies, are considered. 8 Furthermore, in our analysis the use of unit costs and resource utilization-based costs permits a better comparison with other institutions.
Since multiple sequential transplants are becoming used more than a single one in the HDC setting for patients with breast cancer, the main purpose of our study was to determine the economic impact of single or tandem HDC and PBPC support. The cost of a single PBPCT resulting from our analysis was 20 816.63 Euro, while the cost of tandem PBPCT was 38 771.03 Euro. The conditioning and transplant phase and the supportive phase post transplant accounted for between 80% and 90% of the cost. The high cost of these phases were related to the necessary hospitalization.
Our findings are similar to those observed in other European countries and Canada for patients with hematological and non-hematological malignancies: in France the costs ranged from 19 770 to 35 381 USD, 12, 13 in The Netherlands it was 21 809 USD 14 and in Spain was 21 445 USD. 15 In previous Italian studies the cost varied from 18 092 to 26 600 USD, [16] [17] [18] in Canada the total costs ranged from approximately 18 890 to 20 162 USD. 19 Among hematological malignancies lymphomas were prevalent, while breast cancer was the most frequent solid tumor. All authors consider together the different pathologies presuming that the transplant costs are similar. In common practice the variety of HDC programs with PBPC support for treating breast cancer is impressive. A joint report from the EORTC and EBMT registers differences in the methods of managing patients: different discharge policies, more than 20 different conditioning regimens, different protective facilities, supportive therapies and procedures in general. 20 Such variability is probably related to the uncertainties about the best ways of treating patients. These differences can influence not only the clinical results but also the costs. In view of this our study was carried out evaluating analytically the transplant costs both to facilitate the recognition of different categories of cost in different HDC programs and to intervene in the most expensive categories for cost savings. The reported costs are related to single transplant using PBPC as rescue. The cost of tandem transplant that we calculated is not comparable with others since this is the first report that analyzed the costs of this therapeutic approach.
The categories of the cost of transplants are driven by professional fees and pharmacy. The two categories together accounted for approximately 60% of transplant costs. Of professional fees nursing was about 60% and medical 40%, while of pharmacy costs immunoglobulin 7S, growth factors and conditioning were the most highly represented. The remaining 40% of the transplant costs were distributed among the other four categories: stem cell harvest, diagnostic and laboratory, blood products and room costs and overhead. The distribution of categories of costs was similar between the single and tandem HDC.
Our study provides further information about PBPCT in breast cancer patients in order to reduce the costs. To make the transplant procedure more economical it is necessary to reduce costs of hospitalization mainly represented by nursing assistance and drugs. 21 Reducing the length of stay in hospital 22, 23 and moving the transplant to an outpatient setting could be the most important interventions. [24] [25] [26] [27] [28] [29] An outpatient transplant can reduce the costs from 10% to 25% mainly through lower hospitalization with savings in professional fees, room cost and partially in pharmacy costs. 25, 29 As reported in the joint study from the EORTC and EBMT, 20 16% of 162 transplant centers from 20 different countries in Europe have an outpatient HDC program, but only a few of these really perform outpatient transplants. To increase outpatient HDC programs we need to standardize the criteria, since too many variables can influence the results in terms of clinical safety and cost. Since hospitalization in an intensive care unit justifies the high cost of nursing assistance that we have observed, hospitalization in a standard ward could be considered.
Among pharmacy costs immunoglobulins were the most expensive drug. Although their use could reduce the risk of infections, the low rate of early infectious complications in breast cancer patients who underwent autologous PBPCT does not justify their routine use. Nowadays in our institutional protocols immunoglobulins are not included in this setting. Growth factors are the second most expensive item in pharmacy costs. Whilst the use of G-CSF for PBPC collection is unquestioned, its role after HDC remains controversial. Although the addition of G-CSF significantly accelerates granulocyte recovery, no clear benefit in terms of lower incidence of infection or antibiotic consumption has been demonstrated. 16, 30, 31 Awaiting larger randomized trials that should clarify the real advantage of G-CSF in this setting, a delayed administration of G-CSF after HDC could be considered. Controlled trials have demonstrated that delaying the use of G-CSF from day +1 to day +7 after HDC does not influence significantly neutrophil recovery. 32, 33 The results of our analysis are considered in the context of a 'routine' transplant without purging or other manipulations. In our experience the introduction of CD34 + selection, for example, increases the cost of a transplant by approximately 10% in a tandem and 17% in a single HDC. The high cost of purging methods of the graft suggests its use only in controlled trials.
We can conclude that an accurate financial analysis of the different phases of the transplant can allow prediction of the economic impact of the whole procedure during the planning phase of this therapeutic approach.
